Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival by Marinoff, Amanda E. et al.
Rethinking childhood ependymoma: a
retrospective, multi-center analysis
reveals poor long-term overall survival
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Marinoff, A. E., C. Ma, D. Guo, M. Snuderl, K. D. Wright, P. E. Manley,
H. Al-Sayegh, et al. 2017. “Rethinking childhood ependymoma: a
retrospective, multi-center analysis reveals poor long-term overall
survival.” Journal of Neuro-Oncology 135 (1): 201-211. doi:10.1007/
s11060-017-2568-8. http://dx.doi.org/10.1007/s11060-017-2568-8.
Published Version doi:10.1007/s11060-017-2568-8
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493157
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Vol.:(0123456789) 
J Neurooncol (2017) 135:201–211 
DOI 10.1007/s11060-017-2568-8
CLINICAL STUDY
Rethinking childhood ependymoma: a retrospective, multi-center 
analysis reveals poor long-term overall survival
Amanda E. Marinoff2  · Clement Ma1 · Dongjing Guo1 · Matija Snuderl2,5 · Karen D. Wright2 · Peter E. Manley2 · 
Hasan Al-Sayegh1 · Claire E. Sinai1 · Nicole J. Ullrich2,4 · Karen Marcus2 · Daphne Haas-Kogan2 · 
Liliana Goumnerova2,3 · Wendy B. London2 · Mark W. Kieran2 · Susan N. Chi2 · Jason Fangusaro6 · 
Pratiti Bandopadhayay2 
Received: 8 March 2017 / Accepted: 13 July 2017 / Published online: 21 July 2017 
© The Author(s) 2017. This article is an open access publication
proportional-hazards models. Overall survival rates were 
compared to those of the SEER cohort. Median follow-up 
time was 11 years. Ten-year OS and PFS were 50 ± 5% and 
29 ± 5%, respectively. Findings were validated in the inde-
pendent SEER cohort, with 10-year OS rates of 52 ± 3%. 
GTR and grade II pathology were associated with signifi-
cantly improved OS. However, GTR was not curative for 
all children. Ten-year OS for patients treated with a GTR 
was 61 ± 7% and PFS was 36 ± 6%. Pathological examina-
tion confirmed most recurrent tumors to be ependymoma, 
and 74% occurred at the primary tumor site. Current treat-
ment paradigms are not sufficient to provide long-term cure 
for children with ependymoma. Our findings highlight the 
urgent need to develop novel treatment approaches for this 
devastating disease.
Keywords Ependymoma · Survival · Resection · Grade · 
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Abstract Ependymoma is the third most common brain 
tumor in children, but there is a paucity of large studies 
with more than 10 years of follow-up examining the long-
term survival and recurrence patterns of this disease. We 
conducted a retrospective chart review of 103 pediatric 
patients with WHO Grades II/III intracranial ependymoma, 
who were treated at Dana-Farber/Boston Children’s Can-
cer and Blood Disorders Center and Chicago’s Ann & 
Robert H. Lurie Children’s Hospital between 1985 and 
2008, and an additional 360 ependymoma patients identi-
fied from the Surveillance Epidemiology and End Results 
(SEER) database. For the institutional cohort, we evalu-
ated clinical and histopathological prognostic factors of 
overall survival (OS) and progression-free survival (PFS) 
using the log-rank test, and univariate and multivariate Cox 
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Introduction
Ependymoma is the third most common brain tumor in 
children, accounting for 6–10% of all intracranial tumors 
[1]. In children, approximately 90% of ependymomas are 
intracranial, with about two-thirds arising within the pos-
terior fossa [2]. Ependymomas are histologically classified 
as grade I (subependymomas and myxopapillary epend-
ymoma), grade II (classic ependymomas), and grade III 
(anaplastic ependymomas) tumors; however histological 
criteria have poor predictive value [3]. Standard therapy 
typically consists of maximal surgical resection, followed 
by post-operative radiation therapy directed at the site 
of the primary tumor [4]. While there is a long history 
of subclassifying ependymoma by histology, currently, 
there exists little treatment stratification for ependymoma, 
and the long-term prognosis for patients with this disease 
remains poorly understood.
In contradistinction to most other primary brain tumors, 
clinical, pathologic, and radiologic factors that influence 
outcomes for patients with ependymoma have not been 
well defined [5]. Although complete resection has long 
been shown to predict better outcomes, research has not 
yielded consistent findings with regard to the prognostic 
significance of other common factors such as age, tumor 
location and tumor grade [6–11]. Recently, however, large-
scale genomic and epigenomic studies have revealed dis-
tinct molecular subgroups associated with differential prog-
noses [12–27].
Compounding these obstacles is the paucity of reports 
that have included large single- or multi-institutional pedi-
atric populations with long-term follow-up. Most previous 
studies report 3- and 5-year survival outcomes [5, 28] and 
those that report longer-term outcomes have included rela-
tively small numbers of patients and/or follow-up time less 
than 10 years [21, 29–34].
We performed detailed outcome analyses with extended 
follow-up on 113 pediatric patients with intracranial epend-
ymoma who were treated at two pediatric institutions 
between 1985 and 2008. In addition, 360 ependymoma 
patients identified from the Surveillance Epidemiology and 
End Results (SEER) database were included as a reference 
population.
Materials and methods
This HIPAA-compliant study was approved by the Insti-
tutional Review Boards of the Dana-Farber Cancer Insti-
tute (DFCI)/ Boston Children’s Hospital (BCH) and Ann 
& Robert H. Lurie Children’s Hospital of Chicago (LCH). 
Many of the patients reported from the LCH cohort have 
been previously reported in a study which evaluated the 
utility of cerebrospinal fluid (CSF) examination in epend-
ymoma patients [35].
Patient cohort
We performed a retrospective review of 463 patients ≤18 
years of age at diagnosis with WHO Grade II and Grade III 
intracranial ependymoma (as defined by the WHO modi-
fied criteria) [36], which included two independent cohorts: 
an institutional cohort and a validation cohort from the Sur-
veillance, Epidemiology, and End Results (SEER) registry 
(1973–2013). The institutional cohort included 113 patients 
who were treated between 1985 and 2008 at DFCI/BCH 
(N = 52) or LCH (N = 61). Of those, 10 patients (4 from 
Boston; 6 from Chicago) were excluded due to presence 
of metastatic disease at diagnosis. The final institutional 
cohort thus included 103 patients (48 from Boston; 55 from 
Chicago).
For the SEER validation cohort, we extracted 1054 
ependymoma patients ≤18 years of age at diagnosis from 
the November 2013, dataset by querying “ICCC site rec 
extended ICD 0 3/WHO 2008” with the term “epend-
ymoma” [37]. In order to match our study’s inclusion crite-
ria (WHO grade II and III ependymoma), we excluded 685 
patients with grade I or unknown grade tumors. A total of 
360 SEER patients were included in the analysis.
Patient clinical histopathology 
and immunohistochemistry data
Patient records were abstracted to obtain information 
regarding date of birth, gender, date of diagnosis, disease 
site, extent of surgical resection, adjuvant therapy including 
radiation and/or chemotherapy, presence and site of recur-
rent disease, date of recurrence, date and disease status at 
last follow-up, including survival.
Surgical resections were graded as gross total resec-
tion (GTR) or subtotal resection (STR) by reviewing the 
post-operative MRI, or if not available, the post-operative 
report. A gross total resection was defined as absence of 
residual disease at the primary tumor site by post-operative 
MRI imaging in most cases and by intra-operative inspec-
tion in those without available imaging. Any residual tumor 
noted at the time of surgical resection was considered a 
subtotal resection. The follow-up duration for each patient 
was calculated. Disease status at follow-up was determined 
from radiology reports. Disease status was classified as no 
evidence for disease (NED), alive with disease, or death 
from disease.
Histopathological features, including architecture (clas-
sic/WHO Grade II or anaplastic/WHO Grade III epend-
ymoma), presence of necrosis, vascular proliferation, and 
mitotic index were determined by a senior neuropathologist 
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for the 48 tumor samples available at DFCI/BCH (MS). 
Immunohistochemistry performed in each of these cases 
enabled analysis of the MIB-1 labeling index, topoisomer-
ase-II alpha (topo-IIα) expression, and expression of p53, 
Bcl-2, and cyclin D. Previous reports indicate that these 
markers may significantly predict survival outcomes in 
children with ependymoma [38]. To characterize MIB-1 
and topoisomerase-II alpha expression, the fraction of 
immunolabeled tumor cell nuclei was expressed as a per-
centage (index). Patients were separated into low and high 
index groups using previously reported cutoffs (MIB-1: 
low index ≤20.5%; high index >20.5%; topo-IIα: low 
index ≤9.4%; high index >9.4%) [39]. The thresholds for 
both indices were less than one standard deviation above 
our mean proliferation rates. Histology at disease recur-
rence was determined subsequent to biopsy, surgical resec-
tion, or autopsy by review by a neuropathologist at DFCI/
BCH or LCH following the WHO 2007 diagnostic criteria 
[36].
Statistical methods
Overall survival (OS) was calculated from date of diag-
nosis to date of death, or until date of last follow-up if the 
patient was alive. Tumor recurrence was defined radiologi-
cally as greater than 25% growth of an existing lesion or 
development of disseminated disease. Progression-free sur-
vival (PFS) was calculated from date of diagnosis to recur-
rence or date of death, or until date of last follow-up if the 
patient was alive.
Fisher’s Exact Test was used to compare categori-
cal factors between groups and Wilcoxon rank-sum test 
was used for continuous factors. Kaplan–Meier curves of 
OS and PFS were generated and log-rank tests were used 
to compare OS and PFS between demographic and clini-
cal factors. We performed multivariate Cox proportional 
hazards regression to identify significant prognostic fac-
tors for OS and PFS; in each model, we started with all sig-
nificant prognostic factors from the univariate analysis and 
performed backwards variable selection to reach the final 
multivariate model, and checked for evidence of non-pro-
portional hazards. All analyses were performed using SAS 
version 9.4 (Cary, NC) and two-sided p values <0.05 were 
considered statistically significant.
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the insti-
tutional cohort are summarized in Table 1. Median age at 
diagnosis of these children was 3.6 years (range 0.6–18.2 
years); 49 (48%) patients were male. Median follow-up 
time was 11 years (range 0.2–28 years). Twenty-five (24%) 
patients had supratentorial ependymomas and 78 (76%) 
had infratentorial tumors. Seventy-five (73%) patients had 
Grade II (non-anaplastic) ependymoma and 28 (27%) had 
Grade III (anaplastic) pathology. GTR was achieved in 64 
(62%) of patients while 39 (38%) had a STR. Adjuvant 
treatment regimens following resection included radiation 
therapy only (41%), chemotherapy only (11%), radiation 
and chemotherapy (40%), or observation only (9%).
When comparing patient characteristics between institu-
tions, the only significant difference was in post-operative 
treatment regimens (p < 0.0001, Table  1); patients treated 
at LCH were more likely to be observed post-operatively 
(17 vs. 0%) or to receive chemotherapy only (21 vs. 0%), 
and less likely to be treated with combined radiation and 
chemotherapy (26 vs. 56%). All other patient characteris-
tics, including age, gender, tumor location, tumor grade, 
and extent of resection, did not differ significantly across 
institutions (p > 0.05).
Histopathological characteristics for 48 patients treated 
at DFCI/BCH are summarized in Supplemental Table  2; 
these data were not available for LCH patients. Tumor 
architecture was classified as classic (Grade II) in 13 
(27%) cases and anaplastic (Grade III) in 35 (73%) cases. 
Necrosis was present in 37 (77%) cases and vascular pro-
liferation was observed in 29 (60%) cases. Immunohisto-
chemistry revealed nuclear positivity of p53 protein in 28 
(58%), Bcl-2 positivity in 42 (88%), and cyclin D positiv-
ity in 36 (75%) of cases. The median number of mitoses 
per HPF was 2.5 (range 0–27). The median MIB-1 LI was 
15.4 (range 0.8–45); 17 (36%) had a MIB-1 LI ≥ 20.5. The 
median topo-IIα expression was 6.1% (0–31%); 14 (29%) 
had topo-II alpha expression ≥9.4%.
The SEER cohort included 360 ≤ 18 years, of which 206 
(57%) were male. Available demographic data is shown in 
Supplemental Table 1. Eight-two (23%) had Grade II (clas-
sic) ependymoma and 281 (77%) had Grade III (anaplastic) 
pathology. 241 (67%) patients received adjuvant radiation 
therapy, 113 (31%) patients did not receive radiation, and in 
7 (2%) cases, use of adjuvant radiation was unknown.
Children with ependymoma exhibit poor long-term 
survival outcomes
Children with ependymoma in the institutional cohort 
exhibited 5-year OS and PFS rates of 67 ± 5% and 39 ± 5%, 
respectively (Fig. 1a, b). However, survival curves did not 
plateau after 5 years; 10  year OS and PFS were 50 ± 5% 
and 29 ± 5%, respectively. We did not observe significant 
differences in OS or PFS between institutions (Supple-
mental Fig. 1; log-rank p ≥ 0.6). Five-year OS was 63 ± 7% 
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for DFCI/BCH patients and 71 ± 6% for LCH patients. We 
observed OS and PFS to continue to decline between 10 
and 20 years.
The SEER cohort exhibited 5- and 10- year OS rates 
of 63 ± 3% and 52 ± 3%, respectively (Fig.  1c). Taken 
together, these data confirm that approximately half of all 
children diagnosed with ependymoma died of their disease 
by 10 years after diagnosis.
Prognostic factors for survival outcomes
Extent of resection, tumor grade and treatment type 
impacted overall survival. In univariate analyses of OS 
(Table  2), tumor grade, extent of resection, and treat-
ment type were significantly associated with OS (log-
rank p ≤ 0.03) (Fig.  2a, b). Grade II pathology was 
associated with significantly improved OS, compared to 
Grade III (anaplastic) pathology (5-year OS = 71 ± 5% vs. 
57 ± 10%; p = 0.026). We confirmed extent of resection 
to be prognostic in our institutional cohort. GTR com-
pared to STR was associated with significantly improved 
OS (5-year OS = 75 ± 5% vs. 54 ± 8%; p = 0.002; Fig. 2). 
Treatment type was significantly associated with OS 
(p < 0.0001); patients who received chemotherapy only 
or combined chemotherapy and radiation as part of their 
first treatment had significantly poorer OS (51 ± 8%) than 
patients treated with all other modalities.
In the multivariate Cox proportional hazards model 
(Table 3), only tumor grade and treatment type remained 
significant (p < 0.03) after backwards selection; the pro-
portional hazards assumption was upheld. In univari-
ate analyses of PFS (Table  2), extent of resection and 
treatment type were significantly associated with PFS 
(p < 0.003) (Fig. 2c); tumor grade did not confer prognos-
tic significance (Fig. 2d). In the multivariate model, only 
Table 1  Patient demographic and clinical characteristics by institution
*Fisher’s exact test was used to test categorical factors and Wilcoxon rank sum test was used for continuous factors
Demographic and clinical characteristics DFCI/BCH (n = 48) LCH (n = 55) All patients (n = 103) p value*
Median (range)
 Age at diagnosis (years) 3.5 (0.6, 18.2) 3.7 (0.6, 16.4) 3.6 (0.6, 18.2) 0.9
 Follow-up time in surviving patients (years) 13.9 (0.7, 27.6) 8.9 (0.17, 21.5) 11 (0.17, 27.6) 0.11
Frequency (%)
 Gender
  Male 25 (52) 24 (44) 49 (48) 0.4
 Tumor location
  Infratentorial 36 (75) 42 (76) 78 (76) 1.0
  Supratentorial 12 (25) 13 (24) 25 (24)
 Tumor grade
  II 35 (73) 40 (73) 75 (73) 1.0
  III 13 (27) 15 (27) 28 (27)
 Site of recurrence
  Local only 19/34 (56) 32/35 (91) 51/69 (74) 0.005
  Intracranial dissemination only 4/34 (12) 1/35 (3) 5/69 (7)
  Distant spine only 3/34 (9) 1/35 (3) 4/69 (6)
  Local + distant spine only 8/34 (24) 1/35 (3) 9/69 (13)
 Extent of resection
 GTR 28 (69) 36 (67) 64 (62) 0.5
  STR 20 (31) 19 (33) 39 (38)
 Treatment
  XRT only 21 (43) 20/53 (38) 41/101 (41) <0.0001
  Chemo only 0 (0) 11/53 (21) 11/101 (11)
  Chemo + XRT 27 (56) 13/53 (26) 40/101 (40)
  Observation 0 (0) 9/53 (17) 9/101 (9)
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adjuvant treatment type remained significant after back-
ward selection.
Although GTR was significantly associated with 
improved survival, it was not curative for all children. 
While 75% (±5%) of all children who underwent a GTR 
were survivors at 5 years past diagnosis, we observed 
late recurrences and deaths. By 10 years, OS for patients 
treated with a GTR was 61 ± 7% and PFS was 36 ± 6%. 
Forty-nine of 64 patients (76%) who underwent a GTR 
had also received adjuvant radiation therapy at diagnosis.
Pathology confirms relapses are due to recurrent 
ependymoma
Pathological examination confirmed recurrent tumors to 
be ependymoma. Forty-two of the 69 patients with recur-
rent disease on imaging (62.7%) underwent a surgical pro-
cedure at first recurrence that enabled pathological confir-
mation of the recurrent tumor. Among these 42 recurrent 
tumors, 39 tumors (93%) were consistent with epend-
ymoma. In five patients (20%) with an initial diagnosis of 
WHO Grade II ependymoma, pathology at last recurrence 
revealed a Grade III ependymoma. Of the remaining four 
tumors, two were reported as high-grade diffuse gliomas 
and one a meningioma. These findings confirm that nearly 
all relapses were due to recurrent ependymoma, rather than 
radiation-associated secondary malignant gliomas.
The majority of relapses occur at the primary tumor 
site, independent of prior use of cranial irradiation
Despite therapy to achieve local disease control, we 
observed the majority of relapses to occur at the local 
tumor site. Among the 69 patients who displayed evidence 
of disease recurrence and could be evaluated for site of 
relapse, 51 (74%) had an isolated local relapse, 9 (13%) 
had concurrent local relapse with metastatic disease to 
the spine, and 4 (6%) had isolated spine metastases, and 5 
(7%) had intracranial dissemination at first recurrence. In 
one case, the site of relapse was unknown. Among the 50 
patients with isolated local disease recurrence, 40 (58%) 
had been treated with radiation therapy. Site of recurrence 
was not significantly influenced by treatment type: 40/58 
(69%) patients who received radiation therapy experienced 
a local recurrence compared to 11/11 (100%) patients who 
did not (p = 0.55). Of those who did not receive radiation 
7/11 (64%) underwent a GTR.
These data suggest that control at the primary site 
remains a major positive predictor of long-term survival. 
Moreover, our data suggest that current strategies for local 
disease control with gross total resection when feasible, fol-
lowed by focal radiation therapy to the primary tumor site, 
are not sufficient to prevent late-occurring relapses and 
deaths.
Discussion
Our series, the largest multi-institutional series of children 
with ependymoma with more than 10 years of median fol-
low-up, demonstrates that children with ependymoma face 
poor long-term survival, even after gross total resection and 
treatment with adjuvant radiotherapy and/or chemotherapy. 
These data suggest that current treatment paradigms are not 
Fig. 1  Kaplan–Meier curves of a overall survival (OS) and b pro-
gression-free survival (PFS) of the study cohort (n = 103) c compari-
son of OS of the study cohort (n = 103) and SEER cohort (n = 360)
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Table 2  Univariate prognostic factors of overall survival and progression free survival
a Restricted to patients who relapsed
*p value of log rank test
Demographic and clinical fac-
tors (n = 103)
Frequency (%) 5-year 
OS ± SE
10-year 
OS ± SE
OS p value* 5-year 
PFS ± SE
10-year 
PFS ± SE
PFS p value*
Institution DFCI/BCH 48 (47) 63 ± 7 48 ± 8 0.6 43 ± 7 30 ± 7 0.8
LCH 55 (53) 71 ± 6 52 ± 9 36 ± 7 27 ± 7
Age at diag-
nosis
<3 years old 43 (42) 73 ± 7 57 ± 8 0.5 40 ± 7 32 ± 7 0.9
≥3 years old 60 (58) 63 ± 6 46 ± 7 39 ± 6 27 ± 6
Gender Male 49 (48) 68 ± 8 47 ± 8 0.6 36 ± 7 25 ± 6 0.3
Female 54 (52) 67 ± 7 54 ± 7 41 ± 7 33 ± 7
Tumor loca-
tion
Infratentorial 78 (76) 65 ± 6 51 ± 6 0.7 41 ± 6 32 ± 5 0.5
Supratentorial 25 (24) 74 ± 9 45 ± 12 34 ± 10 19 ± 8
Tumor grade II 75 (73) 71 ± 5 56 ± 7 0.026 42 ± 6 30 ± 6 0.5
III 28 (27) 57 ± 10 35 ± 16 30 ± 9 25 ± 8
Site of 
 recurrencea
Local only 51/69 (74) 60 ± 7 39 ± 7 0.2 14 ± 5 2 ± 2 0.7
Intracranial 
dissemina-
tion only
5/69 (7) 75 ±  22 50 ± 25 40 ± 22 20 ± 18
Distant spine 
only
4/69 (6) 50 ± 25 50 ± 25 25 ± 22 25 ± 22
Local + Dis-
tant spine
9/69 (13) 44 ± 17 11 ± 10 22 ± 14 0
Extent of 
resection
GTR 64 75 ± 5 61 ± 7 0.002 48 ± 6 36 ± 6 0.0022
STR 39 54 ± 8 32 ± 8 24 ± 7 16 ± 6
Treatment XRT only 41/101 79 ± 7 73 ± 7 <0.0001 50 ± 8 42 ± 8 0.0016
Chemo only 11/101 73 ± 13 45 ± 15 27 ± 13 18 ± 12
Chemo + XRT 40/101 51 ± 8 26 ± 8 26 ± 7 14 ± 6
Observation 9/101 88 ± 12 88 ± 12 63 ± 17 63 ± 17
Histopathologic features 
(n = 48)
Frequency (%) 5-year 
OS ± SE
10-year 
OS ± SE
OS p value* 5-year 
PFS ± SE
10-year 
PFS ± SE
PFS p value*
Architecture Classic (WHO 
Grade II)
13 85 ± 10 67 ± 14 0.2 62 ± 13 44 ± 14 0.4
Anaplastic 
(WHO grade 
III)
35 49 ± 11 38 ± 11 32 ± 10 27 ± 9
Necrosis No 11 82 ± 12 61 ± 15 0.1 36 ± 15 24 ± 14 0.8
Yes 37 57 ± 8 44 ± 9 45 ± 8 32 ± 8
Vascular pro-
liferation
No 19 72 ± 11 61 ± 12 0.18 50 ± 12 39 ± 12 0.4
Yes 29 57 ± 9 38 ± 10 38 ± 9 25 ± 9
P53 status Negative 20 74 ± 10 57 ± 12 0.5 55 ± 11 33 ± 11 0.7
Positive 28 54 ± 10 41 ± 10 34 ± 9 29 ± 9
Blc-2 status Negative 6 100 50 ± 25 0.3 67 ± 19 44 ± 22 0.08
Positive 42 58 ± 8 47 ± 8 39 ± 8 28 ± 7
MIB-1 LI <20.5 31 74 ± 8 49 ± 10 0.9 52 ± 9 32 ± 9 0.8
≥20.5 17 44 ± 12 44 ± 12 25 ± 11 25 ± 11
Topo-II alpha 
expression
<9.4 34 75 ± 8 54 ± 9 0.052 49 ± 9 32 ± 8 0.2
≥9.4 14 36 ± 13 36 ± 13 29 ± 12 29 ± 12
Mitotic index ≤10 40 67 ± 8 49 ± 8 0.3 45 ± 8 31 ± 8 0.4
>10 8 43 ± 19 43 ± 19 29 ± 17 29 ± 17
Cyclin D 
expression
Negative 12 72 ± 14 48 ± 17 0.5 58 ± 14 29 ± 14 0.4
Positive 36 60 ± 8 47 ± 8 37 ± 8 31 ± 8
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curative for the majority of children and that novel thera-
peutic strategies are required for this disease.
We have shown that long-term outcomes for children 
with ependymomas are dismal. We found that 10-year OS 
is 50 ± 5% and PFS is 29 ± 5%. Importantly, these out-
comes are reproduced in two independent academic centers 
and validated with SEER data. Our experience, with 103 
patients and a median of 11 years of follow-up time, is in 
agreement with prior studies with smaller patient cohorts 
and/or shorter follow-up periods [5, 29–33, 40]. While 
Merchant et al. found 5-year OS of 85% and EFS of 74% 
in a prospective study of 153 patients, the median follow-
up period for this study was only 5.3 years, with only 14 
patients alive at 10 years, compared to 38 patients in this 
study [32]. In our study, we found that half of all children 
with ependymoma continue to relapse and die of their dis-
ease after more than a decade from diagnosis. These data 
have potential implications for altering current treatment 
strategies, as well as the approach to counseling patients 
and families on prognosis for ependymoma at initial 
diagnosis.
Importantly, our study reveals that GTR is not curative 
in many children. We found that while 5-year OS is 75 ± 5% 
in children with completely resected tumors, 10-year OS 
drops to 61 ± 7%. It is well established that GTR of epend-
ymoma is the most important clinical predictor of superior 
PFS and OS [32]. We observed that while GTR was asso-
ciated with improved OS and PFS compared to STR, it is 
Fig. 2  Kaplan–Meier curves of overall survival (OS) and progression free survival (PFS) by: (a, c) extent of resection and (b, d) tumor grade
Table 3  Multivariate Cox proportional hazards model for overall 
survival (n = 101)
Predictive factor HR (95% CI) p value
Tumor grade II (Reference)
III 1.9 (1.1–3.5) 0.03
Treatment Chemo + XRT (Reference)
Chemo only 0.7 (0.3–1.6) 0.41
Observation only 0.1 (0–0.7) 0.025
XRT only 0.3 (0.1–0.5) 0.0001
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often insufficient to prevent late-occurring relapses and 
deaths. Thus, even when GTR is possible, the natural his-
tory for many patients treated with the current standard of 
care is recurrence and death from their disease.
Our data suggest that traditional clinical and histo-
pathological variables do not provide a sufficient basis for 
risk stratification of children with ependymoma, and that 
molecular data are needed to inform our understanding of 
patient prognosis. Previous studies have not yielded con-
sistent findings with regard to the prognostic significance 
of tumor grade [1, 4, 5, 7–9, 31, 40]. This heterogeneity 
across studies may reflect the lack of uniform criteria for 
histopathological classification of ependymoma, as well as 
the use of discrete categories to describe a disease that may 
be better understood along a pathological spectrum and 
more meaningfully defined according to molecular sub-
types. In addition to the need to prospectively validate the 
robust molecular classification system proposed by Pajtler 
et al. [18], we expect that elucidating the role of additional 
molecular subgroups, copy number alterations, and epige-
netic alterations will be instrumental to further understand-
ing ependymoma biology and refining patient risk stratifi-
cation. In particular, H3K27me3 immunostaining, which 
has recently been revealed as a promising biomarker in 
posterior fossa ependymomas [41], would be both valuable 
and viable to incorporate into future studies investigating 
outcomes and potential therapeutic targets.
We confirmed that the majority of recurrent tumors are 
histologically ependymomas. Although radiation can cause 
secondary malignancies, 93% of relapses in the institutional 
cohort were due to recurrent ependymoma, most frequently 
at the local tumor site, highlighting the failure of current 
treatment strategies to provide local control and long-term 
cure. In the SEER Cancer Statistics Review, 1975–2000, 
the cumulative incidence of a subsequent cancer develop-
ing among cancer survivors was 5.0% at 5 years and 8.4% 
at 10 years [42]. Given our median follow-up of 11 years, 
the risk of second malignancy in our cohort is comparable 
to the cumulative incidence of second malignancy among 
cancer survivors in that publication. It should be noted, 
however, that our analysis of the incidence of secondary 
malignancies was limited by the relatively small number of 
recurrent tumors available for pathologic review (n = 48), 
as well as limited information regarding the genetic back-
ground and cumulative radiation dose for each patient. It is 
also important to recognize that radiation-induced second 
primaries would be expected to rise with longer follow-up 
periods, with a high incidence of radiation-induced men-
ingiomas arising after exceptionally long latency periods 
(>20 years after irradiation treatment). This further under-
scores the need for large, multi-institutional studies with 
long-term follow-up to assess patient outcomes and opti-
mize surveillance protocols.
Treatment strategies for ependymoma are focused on 
local tumor control [4, 29, 30, 32–34]. However, we have 
observed children to exhibit late recurrences despite such 
treatment. Our data highlights the need to consider other 
therapeutic options for these children and provides a ration-
ale for investigating the role of maintenance therapy after 
local control. The current COG trial ACNS 0831 assesses 
the efficacy of the addition of maintenance chemotherapy 
to standard local treatments [43]. Multi-center collaborative 
and molecularly informed trials are desperately required to 
assess the most effective maintenance therapies for children 
with this disease.
Limitations of this study include those inherent to a ret-
rospective analysis of a rare tumor over a 20-year period 
including variability of imaging technologies across this 
time. In addition, there are limitations to the data obtain-
able from the SEER database. In particular, the quality of 
the data extracted is dependent on how the data are entered 
into the database, histology and radiology results have not 
been centrally reviewed, and there may be considerable 
variability in the grading of ependymomas due to changes 
in the WHO classification system across this time. A fur-
ther limitation to this study is our analysis of supratentorial 
and infratentorial tumors as a single group. While combin-
ing the two molecularly distinct groups may have masked 
differences in outcome between biologically different 
tumors, we found no significant differences in OS or PFS 
between supratentorial and infratentorial tumors on univar-
iate analysis; we thus opted to combine the groups in order 
to more robustly power our analysis.
While this study highlights the poor long-term outcomes 
for children with ependymoma, several questions remain 
to be answered. First, how does the molecular subtyping 
of ependymoma [12–27, 44–46] influence long-term out-
comes, and does it allow long-term risk stratification? Sec-
ond, what is the optimal adjuvant therapy for these children 
and how long should such treatment be considered? Third, 
what is the best strategy to implement targeted small-mol-
ecule inhibitors into upfront therapy? Further studies that 
incorporate long-term outcomes with molecular subtyp-
ing are needed to understand which children are at greatest 
risk for poor outcomes, and conversely, which children are 
likely to be long-term survivors who may be candidates for 
reduced intensity treatment regimens.
We have demonstrated that long-term survival for chil-
dren with ependymoma is poor. Even children who receive 
the most optimal available treatment with GTR and adju-
vant radiotherapy are at risk for relapse and death for more 
than a decade from diagnosis. Our findings highlight the 
urgent need to develop novel approaches for treatment 
that include adjuvant therapy for this devastating disease. 
Future research should focus on incorporating molecular 
subtyping to better understand differential patient prognosis 
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and on reshaping treatment strategies to improve long-term 
outcomes.
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